Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH
December 21st, 2017
9.1K views
We present a new approach to characterize tumor cells. We combined immunofluorescence with DNA fluorescent-in-situ-hybridization to evaluate cells captured by a functionalized medical wire capable of in vivo enriching CTCs directly from patient blood.
Overview
This study introduces a novel method for characterizing tumor cells by integrating immunofluorescence with DNA fluorescent in situ hybridization (FISH). The approach utilizes a functionalized medical wire to enrich circulating tumor cells (CTCs) directly from patient blood, facilitating the identification of key immunophenotypic and genetic markers.
Key Study Components
Area of Science
- Oncology
- Cell Biology
- Diagnostic Methods
Background
- Characterization of circulating tumor cells is crucial for cancer diagnosis and treatment.
- Current methods often lack the ability to simultaneously assess multiple parameters.
- This study aims to improve the detection and analysis of CTCs in non-small-cell lung cancer.
- The protocol can also be adapted for other cancer types, such as breast cancer.
Purpose of Study
- To develop a protocol that combines immunofluorescence and DNA-FISH for CTC characterization.
- To identify therapy-related targets on CTCs.
- To enhance the understanding of tumor cell biology through simultaneous analysis of phenotypic and genetic features.
Methods Used
- Functionalized wire for capturing CTCs from blood samples.
- Immunofluorescence staining to assess immunophenotype.
- DNA-FISH to analyze genetic alterations.
- Microscopy for imaging and data acquisition.
Main Results
- Successful identification of CTCs with specific immunophenotypic markers.
- Detection of genetic alterations associated with tumor characteristics.
- Demonstrated feasibility of the method for various cancer types.
- Protocol allows for reproducibility and ease of use in laboratory settings.
Conclusions
- The combined immunofluorescence and DNA-FISH method is effective for CTC characterization.
- This approach can provide insights into tumor biology and treatment targets.
- Future applications may extend to other malignancies beyond lung cancer.
Frequently Asked Questions
What is the main advantage of this protocol?
The protocol allows for simultaneous identification of phenotypic and genetic parameters in CTCs.
Can this method be applied to other types of cancer?
Yes, while designed for lung cancer, it can also be adapted for breast cancer and potentially others.
What are the key steps in the protocol?
Key steps include capturing CTCs with a functionalized wire, performing immunofluorescence staining, and conducting DNA-FISH.
What equipment is necessary for this method?
A conventional widefield fluorescence microscope and specific reagents for immunofluorescence and FISH are required.
How does this method improve upon existing techniques?
It allows for the simultaneous analysis of multiple parameters, enhancing the understanding of tumor cell characteristics.
Is the handling of the functionalized wire challenging?
Yes, the functionalized tip is fragile, requiring careful handling during the protocol.
Executive Industry Relevance
This method addresses the critical challenge of rare circulating tumor cell (CTC) detection by enabling high-volume blood sampling and simultaneous phenotypic and genetic analysis. By integrating immunofluorescence and DNA FISH on a 3D functionalized wire, it provides a scalable approach for CTC enrichment and characterization directly from peripheral blood. The workflow supports early discovery efforts by delivering multiplexed data on cell surface markers and chromosomal alterations, informing target validation and patient stratification strategies in oncology drug development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic targets through simultaneous detection of EpCAM positivity and ALK gene translocation in captured CTCs.
- Operational Value: Facilitates biological de-risking by correlating phenotypic markers with cytogenetic alterations in a single workflow.
- Predictive Value: Supports portfolio triage by providing multiplexed data on putative CTCs for hypothesis-driven target validation.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream screening by capturing CTCs from large blood volumes (1.5–3 L) via 30-minute wire incubation.
- Reproducibility: Standardizes CTC isolation and immuno-DNA FISH processing on a 3D support, enabling consistent phenotypic and genetic readouts.
- Quantitative Output: Generates measurable immunofluorescence and FISH signals detectable via conventional widefield fluorescence microscopy.
Translational & Preclinical Research
- Disease Relevance: Demonstrated feasibility in NSCLC cell lines (NCI-H3122 and NCI-H1975) for EpCAM and ALK status, supporting translational biomarker alignment.
- Preclinical Continuity: Enables risk-adjusted advancement decisions by linking CTC phenotype to genotype in disease-relevant models.
- Mechanistic De-risking: Reduces ambiguity in CTC characterization by co-localizing protein expression and gene status on individual cells.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through preclinical evaluation, offering a reusable capability for CTC analysis across oncology indications.
- Discovery Biology: Supports hypothesis testing by enabling simultaneous phenotypic and genetic profiling of rare CTC populations.
- Screening: Delivers assay-ready CTC samples with standardized isolation and staining protocols for reliable compound evaluation.
- Analytics: Provides quantitative readouts (EpCAM intensity, ALK FISH signals) that allow comparative analysis across conditions and timepoints.
- Translational Research: Connects discovery findings to preclinical validation through disease-relevant CTC characterization in NSCLC models.
- Enterprise Reuse: Functions as a platform technology adaptable to multiple cancer types (e.g., breast cancer) and diverse antibody/FISH probe combinations.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in CTC biomarker studies by reducing mechanistic ambiguity through correlated phenotyping and genotyping.
- Operational Value: Enhances standardization and scalability via a wire-based system compatible with conventional microscopy and standard reagents.
- Strategic Value: Improves go/no-go decisions by delivering multiparametric CTC data that inform target specificity and patient selection.
- Portfolio Impact: Enables risk-adjusted prioritization of therapeutic candidates based on CTC phenotype-genotype concordance.
Implementation Considerations
- Requires expertise in immunofluorescence, DNA FISH, and delicate handling of functionalized wire tips to prevent damage.
- Depends on access to a conventional widefield fluorescence microscope with appropriate filter sets for DAPI, FITC, and Cy3/Cy5 equivalents.
- Necessitates cross-team standardization of wire preparation, incubation, and imaging protocols to ensure reproducibility across sites.
- Involves adaptation considerations when extending the protocol to different cancer types or alternative phenotypic/genetic markers.
- Includes practical limitations such as the fragility of the wire’s functionalized tip and the need for hazardous material precautions (acetone, ovens).
Biopharma FAQs
Why does simultaneous phenotypic and genetic analysis matter for CTC target validation?
Simultaneous analysis of EpCAM positivity and ALK gene translocation on individual CTCs reduces false positives and confirms co-expression of therapeutic targets, increasing confidence in target validation efforts.
How does isolating CTCs from large blood volumes improve discovery pipeline sensitivity?
Sampling 1.5–3 L of blood via 30-minute wire incubation increases the likelihood of capturing rare CTCs, enabling more reliable detection and downstream analysis in early discovery workflows.
What quantitative measurements enable reliable CTC phenotyping and genotyping?
Immunofluorescence signal intensity for EpCAM and FISH signal presence/absence for ALK translocation provide quantifiable outputs that allow objective comparison of CTC characteristics across samples.
Why are replication requirements critical for cross-functional collaboration in CTC workflows?
Standardized replication of wire-based CTC capture and immuno-DNA FISH processing ensures consistent phenotypic and genetic readouts, supporting reliable data sharing between discovery, screening, and translational teams.
What statistical analysis capabilities are needed before implementing this CTC characterization method?
The method requires basic quantitative analysis of immunofluorescence and FISH signal frequencies and intensities to assess CTC enrichment, marker co-expression, and genetic alteration rates in captured cells.
Chapters in this video
0:05
Title
1:34
Immuno-DNA FISH (Fluorescent In Situ Hybridization) on Wire
2:35
Fixation, Permeabilization, and Immunofluorescence
4:25
3D DNA FISH Day 2
6:08
3D DNA FISH Day 3
7:51
3D Microscope Observation and Analysis
9:01
Results: No Interference Bewteen Immunofluorescence and DNA FISH Signals
9:38
Conclusion
